Clinical trials for hiv

Cohort 3 will undergo non-ablative conditioning with cyclophosphamide, followed infusion of a single high-dose regimen of LVgpduoCAR-T cells.

Following administration of the experimental therapy, HIV medications will be paused for participants in each group during an analytic treatment interruption.

This study seeks to confidentially collect blood from HIV-positive individuals and HIV-negative controls to provide basic scientists with specimens for collaborative studies. Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy a "remission".

In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment interruption ATI. The purpose of this study is to compare the effectiveness of two mobile health technologies text messaging or a mobile app designed to help people take HIV pre-exposure prophylaxis PrEP as directed by the clinic.

Additionally, the study will see whether a change in ART can affect things like waist circumference, metabolic and cardiovascular health, fat and lean mass body composition, bone health, and maintenance of virologic suppression. Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation. A challenge in achieving worldwide HIV eradication is targeting specific marginalized populations who are most likely to benefit from an HIV cure but possess poorer immune responses.

Measures of MA exposure in urine and serum will then be associated with residual virus production, gene expression, cell surface immune marker protein expression, and systemic markers of inflammation. Atherosclerosis in the setting of HIV infection is distinct and includes increased vascular inflammation, worsened endothelial function, and a predominance of non-calcified plaque. These outcomes can be assessed using specialized noninvasive imaging which strongly predict future CV events in the general population.

PCSK9 has emerged as an important pharmacologic target for cholesterol lowering in the general population and recent studies among individuals without HIV have shown that PCSK9 inhibitor therapy is safely tolerated and significantly reduces major CV events in the general population.

This will be a randomized, placebo-controlled study to evaluate the effects of PCSK9 inhibition on vascular inflammation, endothelial function, and non-calcified plaque using a PCSK9 inhibitor called alirocumab. This study will recruit treated individuals with HIV who are aged 40 and older, with known CVD or risk factors for CVD and who have evidence of vascular inflammation at baseline.

The investigators will correlate changes in arterial inflammation and endothelial function with lipids and markers of inflammation and immune activation.

The tertiary objective is to perform a pilot evaluation of the impact of PCSK9 inhibition on non-calcified plaque as measured by coronary CT angiography. Non-calcified plaque measurements will be correlated with changes in lipid parameters and markers of inflammation and immune activation.

The purpose of this study is to understand if taking an antibiotic called doxycycline by mouth as soon as possible after sexual contact without a condom can reduce the risk of sexually transmitted infections STIs , including gonorrhea, chlamydia and syphilis.

The study will also look at the safety of doxycycline PEP and the impact that PEP may have on the bacteria that cause STIs as well as on bacteria that normally live on the body. While doxycycline is approved by the Food and Drug Administration FDA , taking doxycycline immediately after sexual contact to prevent infection is investigational and is not approved by the FDA for this use.

Participants will take part in the study for 1 year. In gene therapy, small stretches of deoxyribonucleic acid DNA called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV Women involved in the criminal justice system have complex and highly stigmatized sexual and substance use risk profiles and are particularly vulnerable to, and experience, high rates of HIV.

Criminal justice settings represent an important opportunity to address health disparities in HIV by linking women, who experience multiple, intersecting stigmas with innovative biomedical HIV prevention strategies, like pre-exposure prophylaxis PrEP. The investigators propose to develop and test a peer-led patient navigation intervention for criminal-justice involved CJI women at risk of HIV acquisition to reduce intersectional stigma and improve uptake and linkage to PrEP services, thereby increasing access to PrEP and decreasing PrEP-related disparities.

This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus HIV -positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas.

This is a single center exploratory imaging study involving one intravenous microdose of [18F]F-AraG followed by whole-body positron emission tomography-magnetic resonance PET-MR imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection.

This randomized phase III trial studies imiquimod or fluorouracil to see how well they work compared to observation in treating patients with high-grade anal squamous skin lesions who are human immunodeficiency virus HIV -positive. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

It is not yet known whether imiquimod or fluorouracil is more effective than observation in treating high-grade anal squamous skin lesions. This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus HIV associated classical Hodgkin lymphoma that has returned after a period of improvement or does not respond to treatment, or solid tumors that have spread to other places in the body or cannot be removed by surgery.

Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ipilimumab is an antibody that acts against a molecule called cytotoxic T-lymphocyte antigen 4 CTLA CTLA-4 controls a part of your immune system by shutting it down.

Nivolumab is a type of antibody that is specific for human programmed cell death 1 PD-1 , a protein that is responsible for destruction of immune cells. Giving ipilimumab with nivolumab may work better in treating patients with HIV associated classical Hodgkin lymphoma or solid tumors compared to ipilimumab with nivolumab alone.

This is a single-center drug distribution and pharmacokinetic study of a single microdose of 18F-raltegravir given to 10 HIV-infected subjects who are either taking or not taking a raltegravir-containing ART regimen. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of SAR, a tri-specific broadly neutralizing antibody against the human immunodeficiency virus HIV.

LaMontagne Lecture Series. Hill Lecture Series. Director, Anthony Fauci, M. Profiles, Awards and Honors. Laboratory of Immunoregulation. Previous Directors. Office of the Director. Division of AIDS. Division of Allergy, Immunology, and Transplantation. Division of Microbiology and Infectious Diseases. Division of Extramural Activities. Division of Clinical Research. Division of Intramural Research. Vaccine Research Center. Organizational Chart. Joseph J. Kinyoun: Father of the NIH.

Joseph Kinyoun: Selected Bibliography. Career Opportunities. Research Training. Autoimmune Diseases Committee. Board of Scientific Counselors Members. Executive Committee. Advisory Council. Advisory and Peer Review Committees. Visitor Information. Skip to Close. Organization History.

Visitor Information Contact Us. In that …. Campaigns Many Federal agencies have developed public awareness and education campaigns to address HIV prevention, treatment, care, and research. More on Campaigns. Ver Mas Recursos. Do you envisi…. This annual observance brings attention to the unique social an…. Today, a p…. Campaigns Many Federal agencies have developed public awareness and education campaigns to address HIV prevention, treatment, care, and research. More on Campaigns.